J F Forbes
Overview
Explore the profile of J F Forbes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
2048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackland S, Gebski V, Zdenkowski N, Wilson A, Green M, Tees S, et al.
Breast Cancer Res Treat
. 2019 Apr;
176(2):357-365.
PMID: 31028610
Purpose: The separate impacts of dose and dose intensity of chemotherapy for metastatic breast cancer remain uncertain. The primary objective of this trial was to compare a short, high-dose, intensive...
2.
Sestak I, Smith S, Howell A, Forbes J, Cuzick J
Ann Oncol
. 2017 Nov;
29(2):504-509.
PMID: 29126161
Background: Anastrozole reduces breast cancer risk in women at high risk, but implementing preventive therapy in clinical practice is difficult. Here, we evaluate adherence to anastrozole in the International Breast...
3.
Zdenkowski N, Forbes J, Boyle F, Kannourakis G, Gill P, Bayliss E, et al.
Ann Oncol
. 2016 Feb;
27(5):806-12.
PMID: 26861603
Background: Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recurrence, breast cancer events continue at a high rate for at least 10 years after completion of therapy....
4.
Juraskova I, Butow P, Bonner C, Bell M, Smith A, Seccombe M, et al.
Br J Cancer
. 2014 Jun;
111(1):1-7.
PMID: 24892447
Background: Decision aids may improve informed consent in clinical trial recruitment, but have not been evaluated in this context. This study investigated whether decision aids (DAs) can reduce decisional difficulties...
5.
McCarthy N, Boyle F, Zdenkowski N, Bull J, Leong E, Simpson A, et al.
Breast
. 2014 Jan;
23(2):142-51.
PMID: 24393617
Background: Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete response (pCR) is prognostic. Epirubicin and cyclophosphamide followed by...
6.
Huober J, Cole B, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, et al.
Breast Cancer Res Treat
. 2013 Dec;
143(1):159-69.
PMID: 24305979
There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen....
7.
Karlsson P, Cole B, Chua B, Price K, Lindtner J, Collins J, et al.
Ann Oncol
. 2012 Jul;
23(11):2852-2858.
PMID: 22776708
Background: Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and target for postmastectomy radiotherapy (PMRT). Patients And Methods: Local, axillary and supraclavicular recurrences were...
8.
Sestak I, Kealy R, Nikoloff M, Fontecha M, Forbes J, Howell A, et al.
Br J Cancer
. 2012 Jun;
107(2):230-3.
PMID: 22735900
Background: Several studies have reported discordant results regarding the impact of the CYP2D6 phenotype on both the effectiveness and the degree of endocrine symptoms associated with tamoxifen. Other studies have...
9.
Barrios C, Forbes J, Jonat W, Conte P, Gradishar W, Buzdar A, et al.
Ann Oncol
. 2012 Feb;
23(6):1378-86.
PMID: 22317766
Background: Hormone receptor-positive advanced breast cancer is an increasing health burden. Although endocrine therapies are recognised as the most beneficial treatments for patients with hormone receptor-positive advanced breast cancer, the...
10.
Almansoori K, Prasad V, Forbes J, Law G, McGann L, Elliott J, et al.
Cryobiology
. 2012 Jan;
64(3):185-91.
PMID: 22274740
Background: Vitrification is a method of cryopreservation by which cells and tissues can be preserved at low temperatures using cryoprotective agents (CPAs) at high concentrations (typically ≥6.0 M) to limit...